Good Laboratory Practice (GLP) compliance does not have to mean building an expensive laboratory infrastructure or adding unnecessary layers of documentation. For pharmaceutical, biotech, medical device, and clinical research organizations, the smarter approach is to understand what FDA actually expects, apply controls according to study risk, and invest resources where they directly protect data quality and integrity. Under 21 CFR Part 58, FDA establishes requirements for nonclinical laboratory studies that support or are intended to support applications for research or marketing permits. These requirements cover study conduct, personnel, facilities, equipment, protocols, standard operating procedures, records, reports, and quality assurance oversight.

The first step toward cost-effective compliance is determining whether a study is actually within the scope of FDA GLP requirements. Part 58 applies to defined nonclinical laboratory studies conducted to determine safety of FDA-regulated products. It does not automatically apply to every laboratory experiment, exploratory investigation, or clinical study. Correctly defining the regulatory scope can prevent organizations from spending money on controls that are unnecessary for a particular activity while ensuring studies intended for FDA submission receive the appropriate level of oversight. A practical GLP compliance strategy should begin with the study design rather than with paperwork. A clear protocol should establish objectives, test and control articles, test systems, procedures, relevant measurements, and planned study activities. Personnel must have appropriate education, training, and experience, while responsibilities should be clearly assigned. FDA’s framework also expects suitable facilities and equipment, controlled procedures, appropriate records, and reliable final reports. Building these expectations into normal laboratory operations can be considerably more economical than trying to reconstruct compliance immediately before an FDA inspection or regulatory submission.

One of the most important—and frequently misunderstood—areas is quality assurance in GLP. FDA expects an independent Quality Assurance Unit (QAU) to monitor significant study activities, conduct inspections or audits at appropriate intervals, review records and reports, and communicate problems that could affect study integrity. A small organization does not necessarily need a large permanent quality department to achieve this objective. Depending on its structure and applicable requirements, it can establish clearly defined responsibilities and appropriately qualified resources while preserving the independence required for meaningful oversight. Cost control is also possible through a risk-based approach to laboratory systems. Organizations should focus attention on activities that could materially affect the reliability, traceability, or interpretation of safety data. Equipment used for critical measurements should be appropriately maintained and controlled; test and control articles should be properly identified and handled; deviations should be documented and assessed; and raw data should remain attributable, accurate, contemporaneous, and traceable. Attempting to treat every laboratory activity as equally critical can increase costs without necessarily improving regulatory confidence.

GLP documentation requirements should likewise support the reconstruction of what happened during a study. SOPs should describe important laboratory and quality processes, while protocols, amendments, raw data, specimen records, analytical information, deviations, and final reports should provide a coherent history of the work. FDA inspections can examine study records and QAU activities, so documentation that exists only to satisfy a checklist—rather than to demonstrate actual control—can become a liability. Technology creates another important consideration. Modern laboratories increasingly depend on computerized systems for data acquisition, processing, storage, and reporting. Organizations should therefore establish appropriate controls for system access, data changes, backups, documentation, and validation or assurance activities based on intended use and risk. Although some newer FDA initiatives emphasize risk-based approaches to software assurance in other regulated environments, companies should avoid assuming that one framework automatically replaces the specific expectations applicable to GLP studies. The objective remains reliable and defensible data throughout the study lifecycle.

For medical device companies, GLP can be particularly important when nonclinical laboratory studies contribute to submissions such as an Investigational Device Exemption (IDE) or Premarket Approval (PMA). FDA states that applicable nonclinical safety studies supporting these submissions should comply with 21 CFR Part 58, and deviations from GLP should be appropriately explained in the submission. For pharmaceutical and biotechnology organizations, the same principle applies: nonclinical safety data must be sufficiently reliable to support regulatory decision-making before exposure to humans and during subsequent development. Recent FDA materials also demonstrate that GLP oversight remains an active compliance area. FDA continues to conduct inspections of nonclinical laboratories for Part 58 compliance, with current agency resources including active inspection information and bioresearch monitoring materials. This makes FDA inspection readiness an ongoing operational responsibility rather than a project that begins only after an inspection notice.

The most economical approach is therefore not to minimize compliance, but to make compliance efficient. Organizations can reduce unnecessary expenditure by defining study scope early, using scalable SOP systems, training personnel according to their responsibilities, maintaining critical equipment appropriately, outsourcing specialized work when justified, and conducting periodic internal assessments. A well-designed nonclinical laboratory study can be both scientifically robust and financially practical when regulatory requirements are integrated into routine operations instead of treated as an additional administrative burden. For organizations seeking a structured understanding of FDA GLP expectations, practical implementation considerations, and compliance strategies, the GLP FDA regulations program provides an opportunity to strengthen internal knowledge and prepare teams for regulatory expectations. Learn more through the FDAmap GLP program.

In conclusion, meeting FDA GLP expectations without breaking the bank is achievable through disciplined planning, proportional controls, effective quality oversight, and strong data governance. The goal is not to create the largest compliance system, but to create one that reliably demonstrates study integrity. For pharmaceutical, biotech, medical device, and clinical research organizations, this approach can reduce avoidable costs while strengthening the credibility of safety data submitted to FDA.